GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent ...
Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...
Mechelen, Belgium Monday, February 17, 2025, 16:00 Hrs [IST] ...
GlobalData on MSN20h
NICE green lights two blood cancer therapies for NHS useBMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...
Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced ...
The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.
Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...
Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in ...
Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback